Clinical verification of homoeopathic medicine Coleus forskohlii

Phase 2

• Conditions: Health Condition 1: J00- Acute nasopharyngitis [common cold]Health Condition 2: R05- CoughHealth Condition 3: R040- EpistaxisHealth Condition 4: R50- Fever of other and unknown originHealth Condition 5: R51- HeadacheHealth Condition 6: M545- Low back painHealth Condition 7: R52- Pain, unspecified

• Registration Number: CTRI/2023/11/059582
• Lead Sponsor: Central Council for Research in Homoeopathy

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 13 November 2023

Recruitment & Eligibility

• Status: ot Yet Recruiting
• Sex: Not specified
• Target Recruitment: 0

Inclusion Criteria

1. Participants presenting with minimum of three signs and symptoms corresponding to the signs and symptoms attributed to the medicines to be verified.

2. Participants presenting with acute or chronic clinical conditions as per the symptomatology mentioned in the ‘Materia Medica’ of the medicines to be verified.

3. Participants who are not taking any homoeopathic medication for their acute presenting complaints.

4. Participants who have not taken any homoeopathic medication for the past one week for their chronic complaints or those agreeing for a washout period of one week for discontinuing ongoing medications.

5. Participants willing to participate in the study and giving written informed consent/ assent.

Exclusion Criteria

1. Participants presenting with the clinical presentations other than the symptomatology mentioned in the ‘Materia Medica’ of the medicines to be verified.

2. Participants with a history of uncontrolled or life-threatening disease/ systemic illness (tuberculosis, cancer, AIDS, diabetes, hypertension, cardiovascular disorders etc.).

3. Any pre-existing psychiatric disorder.

4. Participants taking concomitant medications like immuno-suppressants, hormonal therapies or other Ayush therapies/ herbal medicines etc. for chronic ailments.

5. Substance abuse and/or dependence.

6. Pregnant and lactating women.

7. Participants deemed unfit by the investigator.

8. Participants not willing to give written informed consent/ assent.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
To compare the changes in MYMOP-2 profile scores.Timepoint: At baseline, 1st, 2nd, 3rd, 4th, 5th, 6th and 7th day followed by weekly follow-ups for one month in acute conditions and every 15 days till 6 months in chronic conditions.